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Introduction 
 Newborn screening (NBS) is a well-known and widely accepted activity in public 
health. The majority of babies born in the United States are screened via a biochemical 
blood test for conditions that are difficult to diagnose but require treatment soon after 
birth1. NBS began in the 1960s as a blood test for phenylketonuria (PKU) and additional 
disorders were added to the screening panel as technological advancements, such as 
tandem mass spectrometry (MS/MS), improved detection of many metabolic disorders2. 
Based on the guidelines set forth by the American College of Medical Genetics, the U.S. 
Department of Health Secretary’s Advisory Committee on Heritable Disorders in 
Newborns and Children selects disorders for the recommended uniform screening panel 
(RUSP) if (1) they can be detected 24-48 hours after birth and would not otherwise be 
detected, (2) there is reliable screening method with appropriate sensitivity and 
specificity and (3) there are benefits of early detection and treatment3.  
NBS has been successful; however, the technology used in medicine is quickly 
advancing and NBS programs are faced with the challenge of incorporating new 
technology into their screening protocol to improve detection of disorders4. Next 
generation sequencing (NGS), including whole exome sequencing (WES), is one of 
these new technologies. WES identifies the DNA sequence of the coding region of the 
genome, where it is believed 85% of disease causing genetic variation occurs5. With its 
relatively low cost and ability to provide detailed genetic information, WES is quickly 
becoming a tool with the potential to revolutionize public health, however, the impact of 
its use in the clinic for the benefit on overall health remains unknown6.  
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There are many potential benefits of incorporating WES into NBS as a majority of 
the disorders currently screened for are caused by rare recessive genetic variants.  By 
identifying the genetic factors causing the disorder, a physician can tailor treatment to 
the specific needs of the patient. For example, at least 400 mutations in the PAH gene 
lead to PKU and there are different treatments for the disorder depending on the type of 
mutation7. In addition to using WES to identify the presence of disorders currently 
screened for, it could be used to screen for other conditions that fit the RUSP criteria but 
currently lack a screening method. Adding new disorders to the screening panel, 
however, would require careful consideration of the long-term ethical and psychological 
effects of a diagnosis as well as the degree to which the disorder is medically 
actionable8.  
Three challenges must be addressed before NGS can be incorporated into NBS. 
First, the ability of NGS to detect disorders screened for in NBS must be compared to 
the current method.  Second, additional disorders that cannot be detected by traditional 
screening methods, but can be detected through NGS, should be investigated for 
potential addition to NBS.  Lastly, if NGS is incorporated into NBS and additional 
disorders are added to the screening panel, information about NGS should be provided 
to parents to help them make informed choices to understand the implications of their 
decisions.9 
To address the first challenge, the usefulness of WES as a screening tool must 
be studied to see how well it identifies the presence of disorders currently screened for. 
The clinical use of WES as a diagnostic tool to identify causal variants for rare diseases 
has been successful10 however the effectiveness of WES as a screening tool for RUSP 
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disorders must be analyzed. In other words, WES has been useful when a patient has 
symptoms that suggest a link to a genetic variant, but its ability to identify conditions 
when applied to the general population must be investigated. The presence of a variant 
in a gene associated with a disorder is not enough to indicate that an individual has the 
disorder. There are silent and synonymous variants that do not affect gene function as 
well as variants of uncertain significance (VUS) that have unknown effects on 
phenotype. In the development of a genetic screening test, it is crucial that the test be 
able to detect the presence of a condition but not return many false positives.  Which 
variants best indicate a positive test result must be determined, and many variables 
must be considered, such as (1) the type, location and frequency of the variant, (2) 
whether the variant is known to be pathogenic or not and (3) the consequences of 
providing a false positive for the associated condition. 
The selection criteria for which genetic variants are expected to indicate a 
positive test result in NBS must be analyzed for each gene associated with a RUSP 
condition to create a screening test with a high positive predictive value (PPV). The PPV 
of a screening test is the proportion of positive results that are true positives and it is 
calculated from the sensitivity and the specificity of the test as well as the prevalence of 
the condition screened for11. Sensitivity is how well a screening test identifies those who 
have the condition (true positive rate), and specificity is how well it identifies those 
without the condition (true negative rate)12.  
To analyze how well WES could perform in NBS, variant selection algorithms 
(VSA) of increasing sensitivity will be used to screen for genetic variants in 23 genes 
known to cause 25 of the RUSP disorders. The VSAs will simulate WES screening tests 
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that require different types of variants to indicate a positive screen.  As the VSAs 
include more possible types of variants, the predicted sensitivity of the VSA increases 
because the criteria necessary for a positive screen becomes more lenient thus 
increasing the possibility of identifying all disease causing variants. The VSAs will be 
applied to the exome sequence data of a population not expected to have any of the 
RUSP disorders. Thus, any variant detected by the algorithms will be a false positive.  
For each gene, the specificity and the false positive rate (1-specificity) will be calculated 
for every VSA based on the number of positive screens returned. The false positive rate 
will then be compared to the sensitivity of the VSA in a receiver operating characteristic 
(ROC) curve to estimate the PPV of the VSA in each gene.   
ROC curves allow one to tailor the sensitivity cutoff for a screening test to ensure 
that high sensitivity does not sacrifice specificity13. This is particularly important in NBS, 
since a test with high sensitivity and low specificity would identify all disease causing 
variants but would return too many false positives. A screening test with low sensitivity 
and high specificity would not return many false positives but would miss too many 
disease causing variants, in other words, it would return false negatives. The ROC 
curves for each gene will be analyzed and used to tailor the appropriate of screening 
tests for each gene depending on the downstream clinical implications of a positive test 
result.  
Method 
Exome Sequences 
Two rounds of VSAs, each with increasing sensitivity, were run on a database of 
exome sequence variants of 619 individuals. This exome sequence data was obtained 
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from the North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing 
(NCGENES) project that conducted WES on individuals with conditions such as cancer, 
cardiogenetic diseases, neurodevelopmental disorders, and retinal diseases14.   
 The annotated variants from the NCGENES exome sequences were accessed 
through a Postgres-SQL database15. Variants accessed from the database were 
annotated with the type of mutation, National Center for Biotechnology Information 
ClinVar database16 classification, Human Genome Mutation Database17 (HGMD) 
classification, conserved functional domain from the RefSeq database18 and the 
maximum allele frequency from the Exome Aggregation Consortium (EXAC)19.  
Prevalence of the Conditions 
  The prevalences of the 25 selected RUSP disorders20 were estimated based on 
the overall prevalence from the study “Birth prevalence of disorders detectable through 
newborn screening by race/ethnicity” 21 which investigated the prevalence of these 
disorders in newborns in California.  The prevalences from this study were useful, 
because California is a good representation of the general population as it is a large 
state with a diverse population.  The prevalences of each condition were rounded down 
and the associated genes were placed in groups according to those prevalences (see 
Appendix I). The associated genes were grouped as prevalences of 
!!",!!! , !!"",!!!, and !!,!!!,!!!.  The expected allele frequency for each prevalence group was determined 
using the Hardy Weinberg Equilibrium equation. Knowing allele frequency is important, 
because a genetic variant suspected to cause disease should not be at an EXAC 
maximum allele frequency higher than the allele frequency calculated from the 
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prevalence of disease.  If a variant has a maximum allele frequency higher than the 
calculated allele frequency for the disorder then the variant is believed be more 
common than the disease-causing variant.  
Table. 1 The prevalence groupings and calculated frequency for each gene. 
         *Variants in HBB are more common in African populations  
 
Variant Selection Algorithms (VSAs)  
Since this study screened for recessive conditions, an individual must have two 
variants in the same gene that meet the criteria specified by the VSA in order to return a 
positive result. The VSAs also only selected variants if the EXAC maximum allele 
frequency was below the calculated allele frequency for the prevalence group of the 
associated condition. Five VSAs were used in the first round(Table 2). The VSAs 
increase in sensitivity with VSA 1 as the least sensitive and VSA 5 as the most 
sensitive. For example, VSA1 is the least sensitive because it only allows variants that 
are labeled ‘pathogenic’ to count as a positive screen. VSA 2 increases in sensitivity as 
it allows the types of mutations that are often disease causing to count as a positive 
screen but may not be labeled ‘pathogenic’. Although it may seem reasonable to only 
screen for variants that are known to be pathogenic, a screening test must also be able 
to identify novel variants that would cause a RUSP disorder. The VSAs are also 
Prevalence Frequency 
Limit 
Genes 
1/10,000 0.01* HBB 
 
1/100,000 
 
0.003 
ACADM, ACADVL, BTD, GALT, MUT, PAH, 
SLC22A5, MCCC1, MCCC2, MMAA, MMAB 
 
1/1,000,000 
 
0.001 
CBS, HMGCL, IVD, ACAT1, ASL, HADHA, 
HADHB, HLCS, PCCA, PCCB, FAH 
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additive, so VSA 2 includes all variants that matched the selection criteria for VSA 2 as 
well as the selection criteria for VSA 1.  
 
Table 2:  The first round of VSAs. VSAs increase in sensitivity with from VSA 1 – 5 
VSA                               Selection Criteria 
VSA 1 ClinVar assertion is 'pathogenic' 
VSA 2 Nonsense, stop-loss, splice site, splice site UTR, frame-shifting indel, 
nonsense indel  
VSA 3 ClinVar assertion 'likely pathogenic' or is labeled disease causing 
mutation ('DM') in the Human Gene Mutation Database (HGMD).  
VSA 4 Missense, boundary crossing indels, potential RNA editing site and non 
frameshifting indels with CADD22scores greater than 13 
VSA 5 All rare missense variants 
 
The first round of VSAs did not return many variants. Having the same selection 
parameters as VSAs used in a study investigating the use of genome screening to 
detect dominant disorders23 is likely a contributing factor to why there were so few 
positive results. Dominant disorders only require one variant to return a positive screen 
whereas recessive disorders require two variants to return a positive screen.  A second 
round of VSAs with a broader range of sensitivity was created to determine the level of 
sensitivity that reduced the specificity of the VSAs. VSAs 7-11 in the second round had 
high sensitivity because they included variants in the selection criteria that are not often 
disease causing, such as variants in the untranslated region (UTR) and introns, both of 
which are non-coding regions. Once again the VSAs increase in sensitivity with VSA 1 
as the least sensitive and VSA 11 as the most sensitive. 
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Table 3. The second round of VSAs. VSAs increase in sensitivity with from VSA 1-11 
VSA Selection Criteria 
VSA 1 ClinVar pathogenic or likely pathogenic 
VSA 2 Truncating (nonsense, frame-shift, canonical splice site, start codon 
mutation) 
VSA 3 Missense and in-frame indels with CADD > 13 
VSA 4 Missense and in-frame indels in conserved domains 
VSA 5 Missense and in-frame indels 
VSA 6 Labeled disease mutations (‘DM’) in HGMD  
VSA 7  Near splice site (+/-3 to +/- 10 in intron) 
VSA 8  Synonymous 
VSA 9  UTR 
VSA 10 Deep intronic variants 
VSA 11 Rare 
 
Receiver Operating Characteristic (ROC) Curve Analysis 
  The specificity of the individual VSAs for each gene was calculated using the 
number of false positives detected.  
 
For both rounds, the VSAs, with increasing sensitivity (true positive rate), were plotted 
against the false positive rate (1 – specificity) to produce a curve similar to a ROC curve 
for each gene.  ROC curves compare the sensitivity and false positive rate of a 
screening test and are used to estimate the predictive strength of a test by calculating 
the area under the curve24. More area under the curve indicates a better predictive 
Specificity  =  (True Negatives– False Positives) /  (True Negatives) 
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value of the test.  The curves for each gene can be used to assign a sensitivity cutoff 
that provides a test with the highest predictive value.  
                                                                                                                      
Fig. 1     
A model Receiver 
Operating 
Characteristic Curve 
(ROC)25. Sensitivity (true 
positive rate) is plotted on 
the y-axis against 1-
specificty (false positive 
rate) on the x-axis. The 
predictive strength of a 
screening test can be 
estimated by calculating 
the area under the curve.  
A is the screening test 
with the strongest 
predictive power with no 
false positives detected 
at the highest sensitivity 
and the area under the 
curve equal to 1. C is the 
screening test with 
poorest predictive power 
with the area under the 
curve equal to 0.5. 
 
Results 
 Two rounds of variant selection algorithms were applied to the NCGENES 
database. It was assumed that the participants in NGGENES did not have any of the 
disorders screened for in NBS. Therefore, any variant identified by a VSA in this 
population would be considered a false positive. Curves were created for the genes 
associated with the disorders screened for in NBS. The VSAs, in increasing sensitivity, 
were plotted against the false positive rate. Curves were created for both round of VSAs 
applied.  
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The first round of VSAs returned fewer positive results than the second round of 
more sensitive VSAs overall. For the gene BTD, both rounds of VSAs returned positive 
results. Actually, the first round of VSAs returned positive results only for BTD in VSAs 
2-5 (Fig.2B), and did not return positive results for any other genes (Fig.2A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Curves for the first round of VSAs applied to each gene. The VSAs increase 
in sensitivity from VSA 1 as the least sensitive to VSA 5 as the most sensitive. The 
VSAs are plotted against the corresponding false positive rate. (A) The curve for all 
genes except BTD. None of these genes returned positive results. (B) The curve for 
BTD. VSAs 2-5 for BTD returned three positive screens.  
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Fig 3. Curves for the second round of VSAs. The VSAs increase in sensitivity from VSA 1 
as the least sensitive to VSA 11 as the most sensitive. The VSAs are plotted against the 
corresponding false positive rate (1-specificity). (A) Individual curves for genes that returned 
positive results and (B) a general curve for genes that did not return positive results. The 
genes that did not return positive results are HHB, GALT, MUT, MMAA, MMAB, HMGCL, 
HLCS, ACAT1, ASL, AND FAH. 
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The second round of VSAs (Fig. 3) returned the most positive results (Fig. 3 A) in 
VSA10 and VSA11, which screened for deep intronic variants and any rare variant, 
respectively. Most genes did not have any positive results for the other VSAs besides 
VSA10 and VSA11. The exceptions were BTD, which had positive results for VSAs 2-11 
and PCAA, which had positive results for VSAs 9-11. 
Table 4. Positive screen results for round 2 VSAs 1-9. The genes BTD and PCCA were the 
only genes to return positive results in any of the VSAs besides VSA10 and VSA 11. These 
results are shown below. The VSA when the pair of variants was first detected is listed as well as 
the number of times the pair was detected in that VSA.  
VSA 1st 
Detected 
Number of 
Occurrences 
Gene Chromosome Position Type Ref 
Allele 
Alt 
Allele 
  
   VSA 2 
       
         3 
BTD 3 15676989' frameshifting'
indel'
TG' 7'
BTD 3 15676986' frameshifting'
indel'
GG' 7'
 
   VSA 9 
 
         1 
PCCA 13 100741464' synonymous' G' T'
PCCA 13 101182477' UTR73' TCAC' 7'
  
The gene BTD is associated with biotinidase deficiency and the gene PCCA is 
associated with propionic acidemia. The variants were not found on the EXAC database 
and are likely to be rare non-pathogenic variants. Although none of the detected variants 
were found in the database, a pathogenic missense variant (rs119103232) G to A 
substitution was found to occur at the same location as the detected variant on 
chromosome 3 position 15676986 in the gene BTD26.  There is a mild and severe form of 
biotinidase deficiency (Appendix I) and it is possible that the detected variants are 
possibly associated with the mild form of the disorder. The variants detected in the gene 
BTD could also be hypomorphic and require an additional severe mutation in the other 
allele for the severe form of biotinidase deficiency.  
 
! 13!
Discussion 
The specificity was high for the most sensitive VSAs in both rounds of VSAs 
applied. This suggests that a genetic screening test for NBS disorders could have high 
sensitivity without jeopardizing specificity. The high level of specificity, even for the most 
sensitive VSAs, may be because the NBS disorders are recessive disorders and two 
variants in a gene were required to meet the selection criteria in order to indicate a 
positive result. Additionally, as these are rare disorders, it would be unlikely that 
someone without the disease would have two rare variants in the same gene due to low 
allele frequencies.  
It is reasonable that VSA10 and VSA 11 in the second round of VSAs returned 
the most positive screens, as they were the most sensitive VSAs. VSA 10 screened for 
deep intronic variants and VSA 11 screened for any rare variant. Introns do not code for 
protein and any variant that is deep in the intron and not near an exon splice site is not 
likely to affect phenotype. Often, VSA 10 and VSA 11 returned the same amount of 
positive screens in each VSA, which is also reasonable because there are not many 
other types of variants besides those already screened for in VSA 1-10. 
  Future studies could further increase the sensitivity of the VSAs by allowing the 
frequency requirements to be more lenient and monitoring the effect on specificity. The 
calculated variant allele frequencies, used as a cutoff for the selected variants, were 
calculated using the prevalences from the prevalence groupings. In an attempt to 
reduce the number of variants above the variant allele frequency for a gene, the 
prevalences were rounded down when grouped. For example, GALT is associated with 
a disorder at a prevalence of 5 out of 100,000 and would be placed in the group 1 out of 
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100,000. Because the variant allele frequency for all genes in that group was based on 
the variant allele frequency for a prevalence of 1 out of 100,000, variants in GALT 
detected with maximum allele frequency at the frequency for the prevalence of 5 out of 
100,000 but above the group frequency would not be included as a positive result. 
Additionally, variants had to be at a maximum allele frequency less than the calculated 
variant frequency, so a variant with maximum allele exactly at the calculated variant 
frequency would not be included as a positive result.  
Issues regarding frequency can be investigated by being more lenient with the 
variant allele frequencies required. Each VSA could have two versions, one with a strict 
variant allele frequency and another with a more lenient one. Additionally, the 
prevalence groupings could be made with smaller ranges between the least prevalent 
and most prevalent conditions in a group.   
  Furthermore, some disease causing variants are more common in certain 
populations than others, as seen in the gene HBB associated with sickle cell disease. 
Although the VSAs were run with the calculated allele frequency from the overall 
prevalence of sickle cell disease in the general population, it is likely that variants 
causing sickle cell would not have been detected if the VSAs were run on a population 
of individuals known to have sickle cell disease. Sickle cell disease is more prevalent in 
African populations, meaning the variant occurs at a maximum allele frequency in the 
African population much higher than the calculated variant allele frequency from the 
overall population. An individual with a variant at the maximum allele frequency for 
sickle cell in African populations would not be detected by the VSAs because the 
maximum allele frequency would be too high. The allele frequency requirements of the 
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VSAs would need to be adjusted if run on a gene associated with a disease more 
prevalent in certain populations. 
Overall, this study was successful at determining the specificity of the VSAs. The 
created curves can be used as a tool to estimate PPV of using WES to screen for 
RUSP disorders in each gene; however, specificity alone is not enough to accurately 
calculate the PPV. The sensitivity of the VSAs is also needed to calculate the PPV and 
create an effective screening test. Sensitivity will be measured by examining how well 
the VSAs identify true positives by running the VSAs on a population of individuals with 
the RUSP conditions. Additionally, although the VSAs are assumed to be increasing in 
sensitivity, they must be experimentally tested. For example, VSA 6 is thought to be 
more sensitive than VSA 4, however VSA 6 may actually be less sensitive than VSA 4 
and identify less true positives. Experimentally measuring the sensitivity of the VSAs 
would also reveal whether the VSAs have different orders of sensitivity depending on 
the gene. VSA 6 may be more sensitive than VSA 4 in one gene but less sensitive than 
VSA 4 in another. 
With further investigation and the calculation of VSA sensitivity, the proper 
selection criteria for which variants detected through sequencing in genes associated 
disorders screened for in NBS can be determined based on the specificity and 
sensitivity. Downstream effects of a positive result, the risks associated with false 
positives, degrees of how medically actionable a disorder is and whether or not there is 
a confirmatory blood test must be carefully considered when determining what selection 
criteria to use as indication of a positive test result if WES is to be incorporated into NBS 
in the future.            
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Appendix   
I. 
Gene Disorder California  Prevalence27 
(per 100,000) 
Grouping 
ACADM Medium-chain acyl-CoA 
 dehydrogenase deficiency ( 
MCAD)  
5.3 1/100,000 
ACADVL Very long-chain acyl-CoA  
dehydrogenase deficiency 
(VLCAD)  
1.8     1/100,000 
BTD Biotinidase deficiency (BIO) 
profound 
1.7 1/100,000 
Biotinidase deficiency (BIO) 
partial 
2.2 1/100,000 
CBS Homocystinuria (cystathionine 
beta synthase) (HCY) 
0 1/1,000,000 
FAH Tyrosinemia 0.1* 1/1,000,000 
GALT Galactosemia/galactose-1-
phosphate uridyltransferase 
deficiency (GALT ) 
1.3 1/100,000 
Galactosemia (Duarte)  5.6 1/100,000 
HBB Sickle cell anemia 10.6 1/10,000 
Beta - Thalassemia 0.7 
HMGCL 3-Hydroxy-3-methylglutaryl-CoA 
lyase deficiency (HMG)  
0 1/1,000,000 
IVD Isovaleric acidemia/ Isovaleryl-
Co-A dehydrogenase deficiency 
(IVA)  
0.9 1/1,000,000 
MUT Methylmalonic aciduria (MMA)  .8 - 1.4  1/100,000 
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PAH Phenylketonuria/Hyperphenylala
ninemia (PKU)  
2.9 1/100,000 
SLC22A5 Carnitine uptake defect/carnitine 
transport defect (CUD)  
1.5 1/100,000 
ACAT1 Beta-ketothiolase (BKT)/ 
Short-chain keto acylthiolase 
deficiency (SKAT)  
0.1 1/1,000,000 
ASL Argininosuccinic aciduria (ASA)  0.2 1/1,000,000 
HADHA Trifunctional protein deficiency 
(TFP)  
0 1/1,000,000 
HADHB Trifunctional protein deficiency 
(TFP)  
0 1/1,000,000 
HLCS Multiple carboxylase deficiency 
(MCD)  
0.1 1/1,000,000 
MCCC1 3-methylcrotonyl-CoA 
carboxylase deficiency (3-MCC) 
2.9 1/100,000 
MCCC2 3-methylcrotonyl-CoA 
carboxylase deficiency (3-MCC) 
2.9 1/100,000 
MMAA Methylmalonic aciduria (MMA)  .8 - 1.4 1/100,000 
MMAB Methylmalonia aciduria (MMA)  .8 - 1.4 1/100,000 
PCCA Propionic acidemia  0.2 1/1,000,000 
PCCB Propionic acidemia  0.2 1/1,000,000 
The RUSP newborn screening disorders and the associated gene and condition 
prevalence from “Birth prevalence of disorders detectable through newborn screening 
by race/ethnicity”. The assigned grouping for each gene is also shown.  
 
*The technology to detect Tyrosinemia came out halfway through the California study so 
the prevalence is from Gene Reviews28. 
